 Connection
Brad Constant to Humans
This is a "connection" page, showing publications Brad Constant has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.184 |
|
|
|
-
Constant BD, Long MD, Scott FI, Higgins PDR. Insurer-Mandated Medication Utilization Barriers are Associated With Decreased Insurance Satisfaction and Adverse Clinical Outcomes: An Inflammatory Bowel Disease Partners Survey. Am J Gastroenterol. 2024 Oct 01; 119(10):2070-2078.
Score: 0.023
-
Constant BD, Scott FI. The PA System: Is Prior Authorization for Dose Escalation of IBD Biologic Therapy a Tolerable Alternative or a Perpetual Annoyance? Dig Dis Sci. 2023 12; 68(12):4279-4281.
Score: 0.022
-
Constant BD, Albenberg L, Mitchel EB, De Zoeten EF, Clapp JT, Scott FI. Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey. Clin Gastroenterol Hepatol. 2024 02; 22(2):423-426.
Score: 0.022
-
Constant BD, Baldassano R, Kirsch J, Mitchel EB, Stein R, Albenberg L. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2022 12 01; 75(6):724-730.
Score: 0.021
-
Constant BD, de Zoeten EF, Weinman JP, Albenberg L, Scott FI. Early Anti-Tumor-Necrosis-Factor Therapy for Crohn's Disease-Related Abdominal Abscesses and Phlegmon in Children. Dig Dis Sci. 2023 03; 68(3):877-888.
Score: 0.021
-
Constant BD, de Zoeten EF, Stahl MG, Vajravelu RK, Lewis JD, Fennimore B, Gerich ME, Scott FI. Delays Related to Prior Authorization in Inflammatory Bowel Disease. Pediatrics. 2022 03 01; 149(3).
Score: 0.020
-
Constant BD, Dutmer CM, Arnold MA, Hall C, Abbott JK, de Zoeten EF. Cytotoxic T-Lymphocyte-Associated Antigen 4 Haploinsufficiency Mimics Difficult-to-Treat Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 04; 20(4):e696-e702.
Score: 0.019
-
Constant BD, Khushal S, Jiang J, Bost JE, Chaisson E, Conklin LS. Early Inflammatory Markers are Associated With Inadequate Post-Induction Infliximab Trough in Pediatric Crohn's Disease. J Pediatr Gastroenterol Nutr. 2021 03 01; 72(3):410-416.
Score: 0.019
-
Mitchel EB, Dolinger MT, Constant B, Wang Z, Guisado D, Gao M, Fusillo S, Baldassano RN, Kelsen J, Dubinsky M, Huang J, Albenberg L. Ustekinumab is safe and effective in pediatric patients with Crohn's disease. J Pediatr Gastroenterol Nutr. 2025 Apr; 80(4):653-663.
Score: 0.006
-
Dawwas GK, Weiss A, Constant BD, Parlett LE, Haynes K, Yang JY, Brensinger C, Wu Q, Pate V, Jonsson Funk M, Schaubel DE, Hurtado-Lorenzo A, David Kappelman M, Lewis JD. Development and Validation of Claims-Based Definitions to Identify Incident and Prevalent Inflammatory Bowel Disease in Administrative Healthcare Databases. Inflamm Bowel Dis. 2023 12 05; 29(12):1993-1996.
Score: 0.006
-
Lewis JD, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, Dawwas GK, Weiss A, Constant BD, McCauley M, Haynes K, Yang JY, Schaubel DE, Hurtado-Lorenzo A, Kappelman MD. Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States. Gastroenterology. 2023 11; 165(5):1197-1205.e2.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|